Article - Limited access to UNIGE
Other version: http://onlinelibrary.wiley.com/store/10.1002/hep.23509/asset/23509_ftp.pdf?v=1&t=h1qf1ryb&s=53c3554bfbdc2cde2a702933d...
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
|Published in||Hepatology. 2010, vol. 51, no. 5, p. 1523-1530|
|Abstract||High systemic levels of interferon-gamma-inducible protein 10 kDa (IP-10) at onset of combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact of IP-10 on the reduction of HCV RNA during therapy remain unclear. In the present study, we correlated pretreatment levels of IP-10 in liver biopsies (n = 73) and plasma (n = 265) with HCV RNA throughout therapy within a phase III treatment trial (DITTO-HCV). Low levels of plasma or intrahepatic IP-10 were strongly associated with a pronounced reduction of HCV RNA during the first 24 hours of treatment in all patients (P < 0.0001 and P = 0.002, respectively) as well as when patients were grouped as genotype 1 or 4 (P = 0.0008 and P = 0.01) and 2 or 3 (P = 0.002, and P = 0.02). Low plasma levels of IP-10 also were predictive of the absolute reduction of HCV RNA (P < 0.0001) and the maximum reduction of HCV RNA in the first 4 days of treatment (P < 0.0001) as well as sustained virological response (genotype 1/4; P < 0.0001). To corroborate the relationship between early viral decline and IP-10, pretreatment plasma samples from an independent phase IV trial for HCV genotypes 2/3 (NORDynamIC trial; n = 382) were analyzed. The results confirmed an association between IP-10 and the immediate reduction of HCV RNA in response to therapy (P = 0.006). In contrast, pretreatment levels of IP-10 in liver or in plasma did not affect the decline of HCV RNA between days 8 and 29, i.e., the second-phase decline, or later time points in any of these cohorts. CONCLUSION: In patients with chronic hepatitis C, low levels of intrahepatic and systemic IP-10 predict a favorable first-phase decline of HCV RNA during therapy with pegylated interferon and ribavirin for genotypes of HCV.|
|Keywords||Adult — Chemokine CXCL10/blood/*metabolism — Drug Therapy, Combination — Female — Hepacivirus/genetics — Hepatitis C, Chronic/drug therapy/*genetics — Humans — Interferon-alpha/administration & dosage/therapeutic use — Liver/metabolism — Male — Middle Aged — Polyethylene Glycols/administration & dosage/therapeutic use — Prognosis — RNA, Viral/*genetics/metabolism — Recombinant Proteins — Ribavirin/administration & dosage/therapeutic use|
|Research group||Etudes et traitement de l'hépatite C et B (554)|
|ASKARIEH, Galia et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. In: Hepatology, 2010, vol. 51, n° 5, p. 1523-1530. https://archive-ouverte.unige.ch/unige:20747|